Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
113
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Chromatin modifying enzymes as modulators of reprogramming

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Generation of induced pluripotent stem cells (iPSCs) by somatic cell reprogramming involves global epigenetic remodeling 1 . While several proteins are known to regulate chromatin marks associated with the distinct epigenetic states of cells before and after reprogramming 2, 3 , the role of specific chromatin modifying enzymes in reprogramming remains to be determined. To address how chromatin-modifying proteins influence reprogramming, we used shRNAs to target genes in DNA and histone methylation pathways, and have identified positive and negative modulators of iPSC generation. While inhibition of the core components of the polycomb repressive complex 1 and 2, including the histone 3 lysine 27 methyltransferase Ezh2, reduced reprogramming efficiency, suppression of SUV39H1, YY1, and Dot1L enhanced reprogramming. Specifically, inhibition of the H3K79 histone methyltransferase Dot1L by shRNA or a small molecule accelerated reprogramming, significantly increased the yield of iPSC colonies, and substituted for Klf4 and c-Myc. Inhibition of Dot1L early in the reprogramming process is associated with a marked increase in two alternative factors, Nanog and Lin28, which play essential functional roles in the enhancement of reprogramming. Genome-wide analysis of H3K79me2 distribution revealed that fibroblast-specific genes associated with the epithelial to mesenchymal transition lose H3K79me2 in the initial phases of reprogramming. Dot1L inhibition facilitates the loss of this mark from genes that are fated to be repressed in the pluripotent state. These findings implicate specific chromatin-modifying enzymes as barriers to or facilitators of reprogramming, and demonstrate how modulation of chromatin-modifying enzymes can be exploited to more efficiently generate iPSCs with fewer exogenous transcription factors.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          Reprogramming of human somatic cells to pluripotency with defined factors.

          Pluripotency pertains to the cells of early embryos that can generate all of the tissues in the organism. Embryonic stem cells are embryo-derived cell lines that retain pluripotency and represent invaluable tools for research into the mechanisms of tissue formation. Recently, murine fibroblasts have been reprogrammed directly to pluripotency by ectopic expression of four transcription factors (Oct4, Sox2, Klf4 and Myc) to yield induced pluripotent stem (iPS) cells. Using these same factors, we have derived iPS cells from fetal, neonatal and adult human primary cells, including dermal fibroblasts isolated from a skin biopsy of a healthy research subject. Human iPS cells resemble embryonic stem cells in morphology and gene expression and in the capacity to form teratomas in immune-deficient mice. These data demonstrate that defined factors can reprogramme human cells to pluripotency, and establish a method whereby patient-specific cells might be established in culture.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Human induced pluripotent stem cells free of vector and transgene sequences.

            Reprogramming differentiated human cells to induced pluripotent stem (iPS) cells has applications in basic biology, drug development, and transplantation. Human iPS cell derivation previously required vectors that integrate into the genome, which can create mutations and limit the utility of the cells in both research and clinical applications. We describe the derivation of human iPS cells with the use of nonintegrating episomal vectors. After removal of the episome, iPS cells completely free of vector and transgene sequences are derived that are similar to human embryonic stem (ES) cells in proliferative and developmental potential. These results demonstrate that reprogramming human somatic cells does not require genomic integration or the continued presence of exogenous reprogramming factors and removes one obstacle to the clinical application of human iPS cells.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells.

              The conversion of lineage-committed cells to induced pluripotent stem cells (iPSCs) by reprogramming is accompanied by a global remodeling of the epigenome, resulting in altered patterns of gene expression. Here we characterize the transcriptional reorganization of large intergenic non-coding RNAs (lincRNAs) that occurs upon derivation of human iPSCs and identify numerous lincRNAs whose expression is linked to pluripotency. Among these, we defined ten lincRNAs whose expression was elevated in iPSCs compared with embryonic stem cells, suggesting that their activation may promote the emergence of iPSCs. Supporting this, our results indicate that these lincRNAs are direct targets of key pluripotency transcription factors. Using loss-of-function and gain-of-function approaches, we found that one such lincRNA (lincRNA-RoR) modulates reprogramming, thus providing a first demonstration for critical functions of lincRNAs in the derivation of pluripotent stem cells.
                Bookmark

                Author and article information

                Journal
                0410462
                6011
                Nature
                Nature
                Nature
                0028-0836
                1476-4687
                5 October 2012
                04 March 2012
                19 November 2012
                : 483
                : 7391
                : 598-602
                Affiliations
                [1 ]Stem Cell Transplantation Program, Division of Pediatric Hematology and Oncology, Manton Center for Orphan Disease Research, Children’s Hospital Boston and Dana Farber Cancer Institute, Boston, Massachusetts, USA
                [2 ]Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA
                [3 ]Harvard Stem Cell Institute, Cambridge, Massachusetts, USA
                [4 ]Stem Cell Program, Children’s Hospital Boston, Boston, Massachusetts, USA
                [5 ]German Cancer Research Center, Heidelberg, Germany
                [6 ]Division of Hematology/Oncology, Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
                [7 ]Department of Pediatric Oncology, Harvard Medical School, Boston, Massachusetts, USA
                [8 ]Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey
                [9 ]Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
                [10 ]Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA
                [11 ]The Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
                [12 ]Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA
                [13 ]Division of Hematology, Brigham and Women’s Hospital, Boston, Massachusetts, USA
                [14 ]Howard Hughes Medical Institute, Chevy Chase, Maryland, USA
                Author notes
                Correspondence and requests for materials should be addressed to: George.Daley@ 123456childrens.harvard.edu

                S.A.A. is a consultant for Epizyme Inc.GQD is a member of the scientific advisory boards and holds stock in or receives consulting fees from the following companies: Johnson & Johnson, Verastem, Epizyme, iPierian, Solasia KK, and MPM Capital, LLP.

                Article
                NIHMS357954
                10.1038/nature10953
                3501145
                22388813
                8937cf9c-b6be-4685-acca-19ff6af7f3be

                Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Funding
                Funded by: National Heart, Lung, and Blood Institute : NHLBI
                Award ID: U01 HL100001 || HL
                Funded by: National Institute of Diabetes and Digestive and Kidney Diseases : NIDDK
                Award ID: R24 DK092760 || DK
                Funded by: Howard Hughes Medical Institute :
                Award ID: || HHMI_
                Categories
                Article

                Uncategorized
                Uncategorized

                Comments

                Comment on this article